Purpose: To report novel clinical manifestations of KCNA2 mutation related epileptic encephalopathy. Methods: Blood samples were sent for whole exome and Sanger sequencing. Seizure types were characterized by clinical criteria and EEG recording. Results: KCNA2 mutations have been reported in 10 cases who presented with focal, absence, generalized tonic-clonic or myoclonic astatic seizures. Here we describe 3 patients with previously unreported, more severe manifestations. Patient 1 is a 5 year-old male with a c.1214 C > T (p.Pro405Leu) mutation, previously reported to be disease causing. He presented at 1 year of age with focal seizures and subsequently developed electrical status epilepticus of sleep at age 3. The latter finding to our knowledge has never been reported in patients with KCNA2 mutations. Patient 2 is a 7 year-old female with a novel c.1195 G > A (p.Val399Met) mutation not previously described. She presented with intermittent then continuous polymyoclonus and myoclonic-astatic and generalized tonic clonic seizures. Continuous polymyoclonus is another new manifestation in patients with KCNA2 mutations. Patient 3 is a 23 year-old male with a c.889C > T (p.Arg297Trp) mutation not previously described. He presented at 4 years of age with generalized tonic clonic seizures and later developed recurrent refractory status epilepticus episodes at ages 19, 22 and 23 years, the latter being a novel manifestation in patients with KCNA2 mutations. Conclusion: We identified 3 patients with KCNA2 mutations with novel characteristics, including electrical status epilepticus of sleep, continuous polymyoclonus and status epilepticus. These results expand KCNA2 mutation epileptic manifestations to include more severe, previously unreported phenotypes.
Introduction
Epileptic encephalopathies are caused by various gene mutations, often affecting ion channels expressed in the brain. Clinical phenotypes associated with gene mutations expand as the field progresses. Mutations in the KCNA2 gene, which encodes the Kv1.2 potassium channel [1] , are a known cause of epileptic encephalopathy. Currently there are, to our knowledge, 10 published cases of KCNA2 related epilepsies with varying degrees of similarity [2] [3] [4] [5] [6] . Patients experienced multiple seizure types that included febrile, focal, complex partial, myoclonic, absence and generalized tonic clonic seizures (GTCS). Here we present 3 additional patients with KCNA2 mutations each with novel, more severe characteristics that expand the epileptic phenotype associated with the underlying mutation.
Case report
Patient 1: Patient 1 presented at 1 year of age with focal seizures. These included: leftward head and eye deviation followed by left-sided focal clonic jerking, sometimes progressing to GTCS. They lasted 1-2 min, and occurred 3 times per month. He had mild speech and motor delay, walking at 14 months of age, using 20 (Fig. 1) . MRI demonstrated non-specific scattered abnormal T2 signal in the frontal and occipital subcortical white matter. His ESES did not respond to nocturnal diazepam or steroid therapy. Thus he started the ketogenic diet. Prior to the ketogenic diet he had 3 GTCS per month. After starting the diet he had 0-1 GTCS per month. Similarly his speech improved, from using 2 word sentences to 4-5 word sentences with increased speech output overall. Ten months after he was diagnosed with ESES, another EEG demonstrated a similar epileptogenic discharge area, however spikes were only present in 50% of the sleep recordings, no longer meeting criteria for ESES. He continued to have a normal neurological exam except for his mild developmental delay.
Whole exome sequencing revealed a c.1214 C > T (p.Pro405Leu) variant in the KCNA2 gene, confirmed by Sanger sequencing. His mother did not have this variant. Paternal sample was not available for analysis. This variant has been reported previously in 3 patients with functional characterization indicating loss of channel function [2] . None of these patients had ESES, making this a novel finding in this condition.
Patient 2: Patient 2 is a 7-year-old female who began having seizures at age 3. She had daily episodes of unilateral clonic jerking of the face and upper extremity on either side. They evolved into GTCS every 6 months. She also had intermittent polymyoclonic jerking of the bilateral facial muscles and extremities multiple times per day, with gradually increasing duration. She had absence seizures lasting several seconds, daily starting at age 4 years. At the age of 5 years she began having episodes of head and body drops, diagnosed as myoclonic astatic seizures of generalized origin. Family history was non-contributory. EEG at the age of 6 years revealed high amplitude diffuse slowing and infrequent generalized posteriorly predominant 4 Hz spike and slow wave activity. Her MRI was normal.
She did not respond to topiramate, lacosamide or to the ketogenic diet. She had a partial response to divalproex, levetiracetam, diazepam and perampanel. At 6 years of age during her first visit to our institution, she had continuous polymyoclonic jerks during wakefulness, as well as two absence seizures a day. Video-EEG monitoring at the age of 7 years demonstrated a slow background with runs of sharp waves in the theta range in the left posterior leads. There was no EEG correlate with her essentially continuous polymyoclonus.
Whole exome sequencing revealed a c.1195 G > A (p. Val399Met) KCNA2 mutation also confirmed by Sanger sequencing. Parental samples were unfortunately unavailable for analysis. This mutation has not been reported previously, but based on in silico analysis, was predicted to be disease causing. This patient's continuous polymyoclonus represents a noteworthy aspect of her epileptic encephalopathy and is a characteristic not reported before.
Patient 3: Patient 3 presented at the age of 4 years with an unprovoked GTCS. His parents also reported staring spells. His development was normal. Family history revealed a first cousin with a history of childhood seizures, and a grandparent with seizures after the age of 70 years. He began taking carbamazepine and was seizure free for several years. He began having breakthrough seizures so was treated sequentially with valproate, phenytoin and lamotrigine. From ages 19 to 23 he had 3 episodes of refractory status epilepticus, all in the setting of low blood levels of antiepileptic agents. The first episode at the age of 19 years lasted 4 hours. He was treated with fosphenytoin and lorazepam. The second episode at the age of 22 years was 98 minures long and he was treated with fosphenytoin, levetiracetam, lorazepam and midazolam boluses. The third episode at the age of 23 years lasted 90 minutes. He was treated again with fosphenytoin, levetiracetam, lorazepam and midazolam boluses. He did not exhibit burst suppression during these episodes. The patient was intubated during all three episodes.
His first EEG at the age of 4 years was abnormal due to continuous polymorphic delta and theta slowing of the posterior dominant rhythm, intermittent bursts of rhythmic 2-2.5 Hz delta activity intermixed with spikes, spike-and-slow wave discharges over the bioccipital regions and isolated parasaggital sharp wave and spike activity during sleep. Later EEGs showed generalized 3 Hz spike and wave activity without clinical accompaniments. His most recent EEG at the age of 23 years showed bifrontal sharp waves, maximal over the left frontal region, and generalized background slowing without well formed awake or asleep background features. His MRI was normal.
During his latest neurological exam, his speech was clear, but not very fluent. His development and the rest of his exam has been otherwise normal and unchanged after the episodes of status epilepticus. Whole exome sequencing of this patient and his parents revealed a de novo c.889 C > T (p.Arg297Trp) KCNA2 gene mutation. This mutation was not confirmed by Sanger sequencing because a sample was not available. This mutation is at the same site as the previously reported p.Arg297Gln mutation, which resulted in a similar disease phenotype with GTCS [2] . This patient, however, harbors a different amino acid substitution and has had a different disease course with multiple episodes of status epilepticus.
Discussion
The KCNA2 gene encodes the central nervous system Kv1.2 potassium channel [1] . Both gain and loss of function mutations in this gene have been associated with the development of epileptic encephalopathy [2] . KCNA2 mutations also cause spastic paraplegia [7] and ataxia [3, 8] . To our knowledge there are only 10 reported cases of KCNA2 associated epilepsy (Table 1) . Our patients have features in common with previously reported patients (Table 1) . However, they also demonstrate additional features not previously described, including electrical status epilepticus of sleep, continuous polymyoclonus and recurrent refractory status epilepticus. In the case of Patient 3, his presumed poor compliance precipitated episodes of status epilepticus. Though patients with epilepsy often have breakthrough seizures due to poor compliance, not all experience recurrent status epilepticus. This patient experienced recurrent refractory status epilepticus, which is a severe condition that has been defined as status epilepticus that continues despite the use of at least one medication other than a benzodiazepine [9] .
Patient 1 had a P405L mutation, a loss of function mutation, which has been reported as a de novo variant in three unrelated individuals with varying degrees of epileptic disease [2] . Patient 2 had a mutation predicted to be disease causing based on in silico analysis. Her clinical picture was also consistent with the previously reported KCNA2 phenotype. Patient 3 possessed a mutation at the same location as one reported previously [2] , however the amino acid substitution is novel. Further work is warranted to investigate whether these two novel mutations represent gain or loss of function mutations. Taken together, these patients expand the KCNA2 mutation phenotype to include novel, somewhat more severe manifestations. Based on our findings, we suggest that physicians caring for patients with epileptic encephalopathies including ESES, recurrent refractory status epilepticus or polymyoclonus should consider the possibility of an underlying KCNA2 mutation. Table 1 Summary of previously reported patients with KCNA2 mutations, as well as the 3 new patients included in this series.
